Blog

The U.S. Food and Drug Administration (FDA) recently approved a ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. Xeris Pharmaceuticals is marketing this new glucagon injection as GVOKE. GVOKE is the first glucagon product approved that can be administered via...

Dimensions in Diabetes 2019, the 5th Annual Program of the Endocrine society in India, provides cutting-edge education to advance knowledge, and stay up to date with the latest evidence based strategies to improve diabetes practice.

While clinical inertia exists, Henry Anhalt, DO says that when physicians listen to their patients with diabetes, it goes a long way towards getting the right treatment for each person.